RestorGenex to Present at BIO CEO & Investor Conference

BUFFALO GROVE, Ill., Feb. 4, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen Simes, chief executive officer of RestorGenex, is scheduled to present at the 17th Annual BIO CEO & Investor Conference in New York City. Mr. Simes will provide a corporate overview on Tuesday, February 10, at 2:30pm ET. The presentation will be webcast and available at http://www.veracast.com/webcasts/bio/ceoinvestor2015/05220285519.cfm.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.

About the BIO CEO & Investor Conference

The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO & Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors.

CONTACT: Trout Group LLC Marcy Nanus, 646-378-2927 mnanus@troutgroup.comSource:RestorGenex